Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Equinorm Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. This suggests that the company's current patent efforts are focused on a single invention or a specific set of claims within a specialized technical group at the USPTO, rather than a broad array of simultaneous filings.
KENYON, JOHN S is the busiest examiner for the company, handling 1 pending office action. This single action constitutes the entire pending workload for the portfolio. The involvement of 1 distinct art unit indicates that the technical review is being conducted by a specific specialized group. Because there is only 1 distinct examiner involved, the company's prosecution strategy is focused on a single point of contact.
Practitioners should note that with only 1 pending office action, the company's immediate legal focus is narrow. The involvement of 1 distinct examiner means the applicant has a single primary contact for their current legal proceedings. This simplified structure allows for a highly targeted response to the 1 pending office action. Resolving the issues raised by KENYON, JOHN S in the 1 distinct art unit is the primary goal for the current portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553471 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | KENYON, JOHN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553471 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | KENYON, JOHN S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18553471 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | KENYON, JOHN S | 1625 | §102§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEquinorm Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
John S Kenyon has the most, with 1 of Equinorm Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
